{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000038","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.146362+00:00","generated_at":"2026-05-27T11:00:32.914960+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit Therapeutics discloses ~$412M cash balance, awards $540K bonuses to CEO/CFO","bullets":["Preliminary unaudited cash, equivalents, and short-term investments ~$412M as of Dec 31, 2024, including $31.8M loan repayment.","CEO Dr. Zanganeh and CFO Manmeet Soni each granted $540K cash bonus for FY2024, payable Q1 2025; no bonus in FY2023.","Base salaries for both officers increase from $600K to $618K, effective February 1, 2025.","Cash balance is preliminary and subject to year-end closing adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000038","json":"https://secwatch.observer/filing/0001599298-25-000038.json","markdown":"https://secwatch.observer/filing/0001599298-25-000038.md","text":"https://secwatch.observer/filing/0001599298-25-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/0001599298-25-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/smmt-20250122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T11:00:32.914960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}